カリフォルニア州におけるT細胞リンパ腫の臨床試験
カリフォルニア州内の拠点で、T細胞リンパ腫に関する13件の研究が参加者を募集しています。
カリフォルニア州内の都市
公式研究テキスト（英語）
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Cedars-Sinai Medical Center, Los Angeles
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- City of Hope National Medical Center, Duarte
- University of California, Irvine, Irvine
- University of California San Francisco, San Francisco
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06561048BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
- City of Hope National Medical Center, Duarte
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/18更新 · NCT04752826Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
- Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank
- City of Hope Comprehensive Cancer Center, Duarte
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
- 他4件
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/14更新 · NCT06724237A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
- City of Hope Comprehensive Cancer Cente, Duarte
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06854653Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
- Rady Children's Hospital, San Diego
被験者募集中第2相
1歳〜18歳 · 全性別 · 2026/08/10更新 · NCT06390319Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
- City of Hope Medical Center, Duarte
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/05更新 · NCT07293403Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
- City of Hope Medical Center, Duarte
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/31更新 · NCT03011814Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas
- City of Hope Medical Center, Duarte
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/05更新 · NCT07278856A Registry for People With T-cell Lymphoma
- City of Hope Cancer Center (Data collection only), Duarte
- UNIVERSITY OF CALIFORNIA SAN DIEGO (Data collection only), San Diego
- University of California San Francisco (Data collection only), San Francisco
- 他1件
被験者募集中観察研究
全年齢 · 全性別 · 2026/05/20更新 · NCT05978141MB-105 in Patients With CD5 Positive T-cell Lymphoma
- University of San Diego (UCSD)-Moores Cancer Center, San Diego
被験者募集中第2相
18歳以上 · 全性別 · 2025/10/03更新 · NCT06534060Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- City of Hope Medical Foundation, Duarte
- University of Southern California, Los Angeles
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/22更新 · NCT04234048Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital Los Angeles, Los Angeles
- Children's Hospital Orange County, Orange
- UCSF School of Medicine, San Francisco
被験者募集中第1相
1歳〜21歳 · 全性別 · 2024/12/06更新 · NCT05476770ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。